NEU Share Price Performance
AU$13.04
0.20 (1.56%)
38.5% undervalued intrinsic discount
AU$21.20
Fair Value
Price AU$13.04
AnalystLowTarget AU$21.20
AnalystConsensusTarget AU$23.45
AnalystHighTarget AU$30.50
Fair ValueAU$21.20
Share Pricen/a
Neuren Pharmaceuticals Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 99 Fair Values set on narratives written by author
NEU Community Narratives
AN
Fair Value
·Fair Value AU$21.2 38.5% undervalued intrinsic discount
US And EU Regulation Will Erode Prospects Yet Offer Hope
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
Fair Value
·Fair Value AU$23.45 44.4% undervalued intrinsic discount
DAYBUE And NNZ-2591 Will Expand Markets While Facing Regulatory Risks
1users have liked this narrative
0users have commented on this narrative
57users have followed this narrative
AN
Fair Value
·Fair Value AU$30.5 57.2% undervalued intrinsic discount
Rising Rett Diagnoses Will Expand Orphan And Pediatric Markets
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
DAYBUE And NNZ-2591 Will Expand Markets While Facing Regulatory Risks
Key Takeaways Strong financial position and partnerships reduce the need for capital raising, protecting margins and earnings. International expansion and R&D investments present significant long-term growth and valuation opportunities.Read more
AN
AU$23.45
44.4% undervalued intrinsic discount
Fair Value
Revenue
-12.77% p.a.
Profit Margin
94.78%
Future PE
25.77x
Price in 2029
AU$28.5
US And EU Regulation Will Erode Prospects Yet Offer Hope
Key Takeaways Heavy reliance on DAYBUE and single-indication focus exposes Neuren to significant revenue concentration and regulatory risk. Growing competition, regulatory pressures, and reimbursement scrutiny threaten future margins and the company's long-term growth potential.Read more
AN
AU$21.2
38.5% undervalued intrinsic discount
Fair Value
Revenue
-22.8% p.a.
Profit Margin
10.64%
Future PE
281.73x
Price in 2028
AU$25.76
Rising Rett Diagnoses Will Expand Orphan And Pediatric Markets
Key Takeaways Rising diagnosis and accelerated international expansion position Neuren for sustained revenue growth and enhanced profit margins ahead of market expectations. Regulatory incentives and expanding patient pools support compounding earnings growth, while disciplined costs and royalty revenue strengthen cash generation and shareholder returns.Read more
AN
AU$30.5
57.2% undervalued intrinsic discount
Fair Value
Revenue
3.05% p.a.
Profit Margin
58.61%
Future PE
30.95x
Price in 2028
AU$37.07
Trending Discussion
Recently Updated Narratives
AN
NEU: Share Buyback Plan Will Support Bullish Long Term Outlook
Fair Value: AU$23.45 44.4% undervalued intrinsic discount
57 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
US And EU Regulation Will Erode Prospects Yet Offer Hope
Fair Value: AU$21.2 38.5% undervalued intrinsic discount
5 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Rett Diagnoses Will Expand Orphan And Pediatric Markets
Fair Value: AU$30.5 57.2% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Neuren Pharmaceuticals Limited Key Details
About NEU
- Founded
- 2001
- Employees
- n/a
- CEO
- WebsiteView website
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
